Extended 78&#37; Hepatectomy in a Mouse Surgical Model

Phillip Brennan; Nyah Patel; Tarek Aridi; Michelle Zhan; Cleide Angolano; Christiane Ferran

doi:10.3791/66528

Epatectomia estesa al 78% in un modello chirurgico murino

JoVE Journal
Biology

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Biology

Extended 78% Hepatectomy in a Mouse Surgical Model

Epatectomia estesa al 78% in un modello chirurgico murino

Full Text

3,627 Views

05:25 min

May 24, 2024

DOI: 10.3791/66528-v

Phillip Brennan¹, Nyah Patel¹, Tarek Aridi¹, Michelle Zhan¹, Cleide Angolano¹, Christiane Ferran^1,2

¹Division of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Department of Surgery,Beth Israel Deaconess Medical Center and Harvard Medical School, ²The Transplant Institute and the Division of Nephrology, Department of Medicine,Beth Israel Deaconess Medical Center and Harvard Medical School

Please note that some of the translations on this page are AI generated. Click here for the English version.

Overview

This study investigates a mouse model of an extended 78% hepatectomy, which better mimics small-for-size syndrome after liver transplantation. The findings indicate a postoperative survival rate of approximately 50% in healthy mice, contrasting sharply with the near 100% survival associated with traditional two-thirds partial hepatectomy.

Key Study Components

Research Area

Liver regeneration and repair
Liver transplantation
Therapeutic strategies for enhancing outcomes

Background

Extended hepatectomies have rarely been explored in literature.
Marginal liver grafts and their risks in transplantation settings are critical challenges.
A focus on gene therapy for hepatocyte protection and regeneration is at the forefront of this research.

Methods Used

Mouse model of extended hepatectomy
Liver-targeted gene therapy
Genomic and proteomic platforms for studying liver biology

Main Results

Successful implementation of a surgical procedure resulting in 50% postoperative survival.
A20 gene therapy demonstrated hepatoprotective functions, improving survival outcomes.
Model serves as a basis to study small-for-size syndrome and therapeutic interventions.

Conclusions

Investigating extended hepatectomies can lead to improved understanding and therapies for liver conditions.
This model can significantly contribute to optimizing liver transplantation strategies.

Frequently Asked Questions

What is the significance of the 78% hepatectomy model?

This model simulates small-for-size syndrome more accurately, allowing research into liver transplantation challenges.

How does the A20 gene therapy work?

A20 provides hepatoprotection through anti-inflammatory and anti-apoptotic mechanisms, enhancing liver regeneration.

What are the postoperative outcomes of the procedure?

The procedure results in approximately 50% postoperative survival compared to nearly 100% in traditional methods.

What are potential applications of this research?

This research could lead to improved therapeutic strategies for liver transplantation and cancer surgeries.

What technologies are utilized in this study?

The study employs genomic, proteomic, and metabolomic platforms to analyze liver regeneration.

Why is liver regeneration important?

Understanding liver regeneration is crucial for improving outcomes in liver diseases and surgeries.

What are the implications for clinical translation?

Pretranslational studies in large animals may pave the way for clinical trials of A20 gene therapies.

Il modello murino di epatectomia parziale 2/3 (66%) è ben descritto in letteratura, ma sono state raramente utilizzate epatectomie più estese che imitano la sindrome di piccole dimensioni dopo trapianto di fegato. Descriviamo una procedura di epatectomia estesa al 78% in un modello murino che si traduce in circa il 50% di letalità postoperatoria nei topi sani.

Lo scopo della nostra ricerca è valutare strategie terapeutiche per migliorare la rigenerazione e la riparazione del fegato che potrebbero aiutare a migliorare i risultati dei pazienti nel contesto del trapianto di fegato utilizzando un trapianto di fegato marginale, nonché la resezione epatica estesa per il cancro che è a più alto rischio di non funzione primaria e insufficienza epatica acuta. Il nostro team utilizza piattaforme genomiche, proteomiche e metabolomiche per studiare la rigenerazione epatica e identificare nuovi bersagli terapeutici per migliorare i risultati. L'obiettivo dei nostri laboratori è quello di sviluppare piattaforme di terapia genica all'avanguardia per veicolare il gene epatoprotettivo e rigenerativo del fegato A20.

Abbiamo scoperto una potente funzione epatoprotettiva per l'A20, chiamato anche TNFAIP3, attraverso le sue funzioni combinate antinfiammatorie, anti-apoptotiche e proliferative negli epatociti. Le terapie geniche A20 mirate al fegato hanno protetto dalla letalità nei modelli murini di epatite tossica, estesa del 78% e epatectomie radicali letali del 90% e anche ischemia epatica prolungata. Recenti e promettenti studi pre-traslazionali su animali di grandi dimensioni preludono alla traduzione clinica di questa terapia.

View the full transcript and gain access to thousands of scientific videos